Osimertinib drug page Clinical trials

Trials with Osimertinib

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

8Trials
2Recruiting
20Countries
8.758Planned patients

Showing 1–8 of 8

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Recruiting Phase 1 416 patients NCT06618287

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

United States, Australia, Canada, Chile and 5 more Feb 2025 – Feb 2031 Interventional
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Recruiting Phase 1 1.000 patients NCT05785741

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.

United States, China Aug 2023 – Apr 2028 Interventional
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Not yet recruiting Phase 1 282 patients NCT07612137

To evaluate the safety and tolerability of IBI3005 combination therapy in participants with advanced solid tumors; to evaluate the antitumor activity of IBI3005 combination therapy in participants with advanced solid tumors.

China Jun 2026 – Jun 2028 Interventional
First in Human Study of AZD9592 in Solid Tumors
Ongoing, not recruiting Phase 1 167 patients NCT05647122

This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharma…

United States, Australia, Canada, China and 7 more Dec 2022 – Aug 2028 Interventional
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Ongoing, not recruiting Phase 1 194 patients NCT04868877

A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid t…

United States, Belgium, France, Germany and 5 more Apr 2021 – Mar 2027 Interventional
Combined with: MCLA-129
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Ongoing, not recruiting Phase 2 6.452 patients NCT02465060

This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearb…

United States, Guam, Puerto Rico Aug 2015 – Dec 2026 Interventional
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
Ongoing, not recruiting Phase 1 237 patients NCT02099058

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumor…

United States, Belgium, Finland, France and 5 more Jan 2014 – Aug 2026 Interventional
Combined with: ErlotinibNivolumab
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastati
Finished Phase 1 10 patients NCT05954871

The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.

United States, Australia, South Korea Jan 2024 – Sept 2025 Interventional
Combined with: CetuximabGDC-1971

Where the recruiting trials are